[go: up one dir, main page]

UY31417A1 - A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION - Google Patents

A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION

Info

Publication number
UY31417A1
UY31417A1 UY31417A UY31417A UY31417A1 UY 31417 A1 UY31417 A1 UY 31417A1 UY 31417 A UY31417 A UY 31417A UY 31417 A UY31417 A UY 31417A UY 31417 A1 UY31417 A1 UY 31417A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
polytherapy
pimecrolimus
everolimus
sirolimus
Prior art date
Application number
UY31417A
Other languages
Spanish (es)
Inventor
Rolando Perez Rodriguez
Ramkrishnan Melarkode
Pradip Nair
Jose Enrique Montero Casimiro
Indira Venkata Chivukula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31417A1 publication Critical patent/UY31417A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe una politerapia, de un agente inhibidor de EGFR que inhibe competitivamente la union del EGF natural al receptor y al inmunosupresor para tratar a un huésped mamífero, preferiblemente humano por administracion de una concentracion terapéuticamente efectiva de un fármaco para la prevencion y/o tratamiento de tumores. Los agentes inmunosupresores preferidos pueden seleccionarse del grupo de sirolimus, tacrolimus, everolimus, pimecrolimus en forma libre o en forma de sal farmacéuticamente aceptable.A polytherapy of an EGFR inhibitor agent that competitively inhibits the binding of natural EGF to the receptor and the immunosuppressant to treat a mammalian host, preferably human by administration of a therapeutically effective concentration of a drug for prevention and / or treatment is described of tumors Preferred immunosuppressive agents may be selected from the group of sirolimus, tacrolimus, everolimus, pimecrolimus in free form or in the form of a pharmaceutically acceptable salt.

UY31417A 2007-10-22 2008-10-22 A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION UY31417A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2373CH2007 2007-10-22

Publications (1)

Publication Number Publication Date
UY31417A1 true UY31417A1 (en) 2009-05-29

Family

ID=40579132

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31417A UY31417A1 (en) 2007-10-22 2008-10-22 A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION

Country Status (5)

Country Link
AR (1) AR072759A1 (en)
CU (1) CU23798B6 (en)
TW (1) TW200942260A (en)
UY (1) UY31417A1 (en)
WO (1) WO2009054001A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
AU2019306092A1 (en) 2018-07-19 2021-02-04 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP2407473A3 (en) * 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
TW200803892A (en) * 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
WO2007059782A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors

Also Published As

Publication number Publication date
CU20090007A6 (en) 2011-07-11
WO2009054001A1 (en) 2009-04-30
CU23798B6 (en) 2012-03-15
TW200942260A (en) 2009-10-16
AR072759A1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
UY31417A1 (en) A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION
Freret et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice
MX2021002886A (en) Combination therapy for the treatment of triple-negative breast cancer.
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
EA200970932A1 (en) METHODS OF TREATMENT WITH THE APPLICATION OF PYRIDOPYRIMIDINONOVES INHIBITORS PI3K ALPHA
ECSP10010034A (en) 2-ANILINOPURIN-8-ONAS AS TTK / MPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
WO2008050329A3 (en) Novel sirnas and methods of use thereof
CR11510A (en) USE OF A GAMMA-SECRETASE INHIBITOR FOR CANCER TREATMENT
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
CL2007001554A1 (en) Compounds derived from pyrido [3,2-e] pyrazines; pde10 inhibitors; preparation process; pharmaceutical composition comprising; pharmaceutical kit; Use to prepare a medication to treat or prevent disorders associated with the hyperactivity of pde10 and / or disorders in which inhibiting pde10 is of value.
EP1765362A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOVASCULAR DISEASES
BR112017007239A2 (en) aurora kinase inhibitor, its uses, and pharmaceutical composition ".
ECSP088762A (en) PAIN TREATMENT
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
RU2008124827A (en) TREATMENT OF NEUROENDOCRINE TUMORS
UY33221A (en) METHODS TO TREAT CANCER USING PI3K AND mTOR INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CL2023000296A1 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
RU2008148597A (en) PHARMACEUTICAL COMBINATIONS
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
CO6361995A2 (en) ISOQUINOLINONE DERIVATIVES AS AN NG3 ANTAGONISTS
AR091724A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION
BR112012020377A2 (en) use of one or more selected from the group consisting of a compound of formula (i), a racemic-diastereomeric mixture and an optical isomer of said compound, and a pharmaceutically acceptable salt and prodrug thereof, method, pharmaceutical composition and treatment kit cachexia and commercial packaging

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171017